BR112019021917A8 - Composições de iodo - Google Patents

Composições de iodo

Info

Publication number
BR112019021917A8
BR112019021917A8 BR112019021917A BR112019021917A BR112019021917A8 BR 112019021917 A8 BR112019021917 A8 BR 112019021917A8 BR 112019021917 A BR112019021917 A BR 112019021917A BR 112019021917 A BR112019021917 A BR 112019021917A BR 112019021917 A8 BR112019021917 A8 BR 112019021917A8
Authority
BR
Brazil
Prior art keywords
compositions
iodine compositions
iodine
microorganisms
treat
Prior art date
Application number
BR112019021917A
Other languages
English (en)
Other versions
BR112019021917A2 (pt
Inventor
Löscher Frank
Grillenberger Ralf
Original Assignee
Novaliq Gmbh
Dermaliq Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh, Dermaliq Therapeutics Inc filed Critical Novaliq Gmbh
Publication of BR112019021917A2 publication Critical patent/BR112019021917A2/pt
Publication of BR112019021917A8 publication Critical patent/BR112019021917A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A presente invenção se refere às composições compreendendo iodo molecular e um veículo compreendendo um alcano semifluorado. As composições da invenção podem ser usadas para tratar ou prevenir doenças ou condições causadas ou associadas aos microrganismos.
BR112019021917A 2017-04-21 2018-04-20 Composições de iodo BR112019021917A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17167561.4 2017-04-21
EP17167561 2017-04-21
PCT/EP2018/060197 WO2018193093A1 (en) 2017-04-21 2018-04-20 Iodine compositions

Publications (2)

Publication Number Publication Date
BR112019021917A2 BR112019021917A2 (pt) 2020-05-26
BR112019021917A8 true BR112019021917A8 (pt) 2023-03-21

Family

ID=58672337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019021917A BR112019021917A8 (pt) 2017-04-21 2018-04-20 Composições de iodo

Country Status (11)

Country Link
US (2) US11273174B2 (pt)
EP (1) EP3612228B1 (pt)
JP (1) JP7072582B2 (pt)
KR (1) KR102351816B1 (pt)
CN (1) CN110678207A (pt)
AU (1) AU2018253944B2 (pt)
BR (1) BR112019021917A8 (pt)
CA (1) CA3058097C (pt)
ES (1) ES2957559T3 (pt)
PL (1) PL3612228T3 (pt)
WO (1) WO2018193093A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108283623A (zh) 2011-05-25 2018-07-17 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
PL3488847T3 (pl) 2012-09-12 2024-04-08 Novaliq Gmbh Kompozycje semifluorowanego alkanu
BR112019001054A2 (pt) 2016-07-21 2019-04-30 Iogen, Llc desinfetantes tópicos emolientes
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
EP3612228B1 (en) * 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
JP2020535156A (ja) 2017-09-27 2020-12-03 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
CN112839620A (zh) * 2018-09-27 2021-05-25 诺瓦利克有限责任公司 脂质屏障修复剂
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
CA3141386A1 (en) * 2019-05-24 2020-12-03 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
EP3861857A1 (en) * 2020-02-07 2021-08-11 Novaliq GmbH Antiparasitic compositions
EP4196094A1 (en) * 2020-08-13 2023-06-21 I2Pure Corp. High molecular iodine concentration compositions, pharmaceutical formulations, preparation and uses

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
JPS5721312A (en) 1980-07-12 1982-02-04 Green Cross Corp:The Breathable ointment
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5849291A (en) 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5464867A (en) * 1994-11-16 1995-11-07 American Home Products Corporation Diaminocyclobutene-3,4-diones
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (pt) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
ATE238751T1 (de) 1998-02-09 2003-05-15 Macrochem Corp Antimykotischer nagellack
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
IL141095A0 (en) 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE322889T1 (de) 1999-02-08 2006-04-15 Alza Corp Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
JP2001058734A (ja) 1999-06-09 2001-03-06 Tohoku Ricoh Co Ltd 印刷装置
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US6592907B2 (en) * 1999-10-04 2003-07-15 Hampar L. Karagoezian Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
PT1423102E (pt) 2001-09-04 2008-02-25 Trommsdorff Arzneimittel Emplastro para o tratamento de disfunções e perturbações o crescimento da unha
US7147873B2 (en) 2002-01-16 2006-12-12 3M Innovative Properties Company Antiseptic compositions and methods
US20050084553A1 (en) * 2002-01-26 2005-04-21 Woong-Sig Moon Composition containing moutan root bark extract as active ingredient
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP2007503428A (ja) 2003-08-25 2007-02-22 フォーミックス エルティーディー． 浸透性医薬発泡剤
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
MXPA06003316A (es) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
JP2007511616A (ja) 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
ES2387619T3 (es) 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
WO2005123035A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
KR20070040381A (ko) 2004-07-01 2007-04-16 셰펜스 아이 리써치 눈의 장애 및 상태를 치료하는 조성물 및 방법
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
WO2007052288A2 (en) 2005-08-05 2007-05-10 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
AR062046A1 (es) 2006-07-25 2008-08-10 Osmotica Pharmaceutical Argentina S A Soluciones oftalmicas
AU2007281918A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
EP2068828A2 (en) 2006-09-29 2009-06-17 SurModics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
JP5569899B2 (ja) 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション 揮発性のフッ化麻酔薬を静脈内送達するためのフルオロポリマーベースのエマルション
WO2008068775A2 (en) 2006-12-07 2008-06-12 Sun Pharmaceutical Industries Limited Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
ATE532505T1 (de) 2008-04-18 2011-11-15 Novaliq Gmbh Inhalative und instillative verwendung von semifluorierten alkanen als wirkstoffträger im intrapulmonalen bereich
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
US8809261B2 (en) 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
US20170044096A1 (en) * 2013-03-15 2017-02-16 Rutgers, The State University Of New Jersey Augmenting Moieties for Anti-Inflammatory Compounds
US20100189765A1 (en) 2008-11-26 2010-07-29 Erickson Signe R Implantable ocular drug delivery device and methods
JP5670200B2 (ja) * 2008-12-02 2015-02-18 ロート製薬株式会社 眼科用組成物
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2010150378A1 (ja) 2009-06-25 2010-12-29 ライオン株式会社 眼科用組成物
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
US20110269704A1 (en) 2009-07-24 2011-11-03 Seigfried Bernd G Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
TWI618539B (zh) 2009-12-15 2018-03-21 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
HUP1000362A2 (en) 2010-07-12 2012-11-28 Egis Gyogyszergyar Nyrt Antiseptic and disinfecting compositions having reduced iodine content
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
ES2549045T3 (es) * 2010-10-20 2015-10-22 Galderma S.A. Método para tratar una infección por el virus del herpes usando un compuesto de lactona macrocíclica
US20120100183A1 (en) 2010-10-23 2012-04-26 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
BR112013016661B1 (pt) 2011-01-04 2021-08-03 Novaliq Gmbh Emulsões de o/a compreendendo alcanos semifluorados
US20120219640A1 (en) 2011-02-25 2012-08-30 Wright Kenneth W Anti-infective solution for athlete's foot
CN108283623A (zh) * 2011-05-25 2018-07-17 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
TW201808311A (zh) * 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
MY166228A (en) 2012-09-12 2018-06-22 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
PL3488847T3 (pl) 2012-09-12 2024-04-08 Novaliq Gmbh Kompozycje semifluorowanego alkanu
SG10201710928PA (en) * 2013-03-14 2018-02-27 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
US9278121B2 (en) * 2013-03-14 2016-03-08 The Board Of Trustees Of The University Of Arkansas Methods of use for an antimicrobial peptide
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
ES2949040T3 (es) 2014-03-31 2023-09-25 Amcor Rigid Plastics Usa Llc Recipiente de liberación controlada
EP3139939B1 (en) * 2014-05-07 2023-09-06 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
WO2016025560A1 (en) 2014-08-13 2016-02-18 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
PT3355990T (pt) 2015-09-30 2019-09-11 Novaliq Gmbh Compostos semifluorados e as suas composições
AU2017281296B2 (en) 2016-06-23 2021-03-11 Novaliq Gmbh Topical administration method
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
CA3036313A1 (en) 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CA3045733C (en) 2016-12-22 2024-01-16 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
CN110267645A (zh) 2016-12-23 2019-09-20 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions

Also Published As

Publication number Publication date
CA3058097A1 (en) 2018-10-25
EP3612228C0 (en) 2023-08-23
AU2018253944B2 (en) 2022-09-15
JP7072582B2 (ja) 2022-05-20
KR102351816B1 (ko) 2022-01-17
AU2018253944A1 (en) 2019-11-07
PL3612228T3 (pl) 2024-04-08
ES2957559T3 (es) 2024-01-22
WO2018193093A1 (en) 2018-10-25
KR20190138866A (ko) 2019-12-16
US20200129543A1 (en) 2020-04-30
JP2020517622A (ja) 2020-06-18
US11273174B2 (en) 2022-03-15
BR112019021917A2 (pt) 2020-05-26
EP3612228A1 (en) 2020-02-26
US20220152096A1 (en) 2022-05-19
CN110678207A (zh) 2020-01-10
EP3612228B1 (en) 2023-08-23
CA3058097C (en) 2024-01-02

Similar Documents

Publication Publication Date Title
BR112019021917A8 (pt) Composições de iodo
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
BR112016028255A2 (pt) agentes imunorreguladores
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
BR112018067689A2 (pt) composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
CL2018003425A1 (es) Composiciones de cannabidiol y usos de las mismas.
EA201790806A1 (ru) Иммунорегулирующие средства
BR112017009277A2 (pt) compostos de silicone
BR112017009623A2 (pt) composição de limpeza
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112017016072A2 (pt) ?composição, curativo de ferida, e, método de fabricação de uma composição?
CO2018009099A2 (es) Tratamiento de condiciones oculares alérgicas con ciclodextrinas
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112017016093A2 (pt) composição sólida, curativo de ferida, e, método de fabricação de uma composição
MY165124A (en) Semifluorinated alkane compositions
BR112016021648A2 (pt) novos compostos
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112017027536A2 (pt) variantes da quimosina com propriedades aperfeiçoadas
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019000849A2 (pt) composições líquidas de limpeza com sistema antibacteriano e método de fabricação das mesmas
BR112019004332A2 (pt) géis injetáveis que compreendem ácido hialurônico reticulado e hidroxiapatita, composição e processo de fabricação dos mesmos
BR112017009731A2 (pt) composição de limpeza
BR112016011472A2 (pt) tienopirimidinas como inibidores de mknk1 e mknk2
BR112017008680A2 (pt) composição de polímero transparente de poliamida modificada por impacto

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: DERMALIQ THERAPEUTICS, INC. (US)